• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

专利的 p53-MDM2 相互作用小分子抑制剂。

Patented small molecule inhibitors of p53-MDM2 interaction.

机构信息

Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Avenue, PSC304A, Los Angeles, California 90089, USA.

出版信息

Expert Opin Ther Pat. 2006 Feb;16(2):165-88. doi: 10.1517/13543776.16.2.165.

DOI:10.1517/13543776.16.2.165
PMID:20141510
Abstract

The interaction between p53 and murine double minute 2 (MDM2) provides an attractive drug target in oncology. Small molecule inhibitors of this interaction have not only provided strong evidence for blocking the protein-protein interaction, but are also extremely useful as biological probes and ultimately as novel therapeutics. Here, a comprehensive review of the patented small molecule inhibitors of the p53-MDM2 interaction are provided. These inhibitors are divided into eight classes of compounds that include cis-imidazolines, benzodiazepines, fused indoles, substituted piperazines, substituted piperidines, aryl boronic acids, spiro-indoles, and alpha-helix mimetic compounds. The best documented class of compounds, cis-imidazolines (e.g., Nutlins) are selective and potent inhibitors of the p53-MDM2 interaction, and selected examples exhibit potency in the nanomolar range. Nutlins induce apoptosis in p53 wild-type cells and show in vivo efficacy in mice xenograft models. Additional strategies briefly discussed in this review, and which are under current exploration in targeting the p53 pathway, include the inhibition of MDM2-mediated p53 ubiquitylation and restoration of DNA-binding activity of mutant p53 protein using small molecules.

摘要

p53 和鼠双微体 2(MDM2)之间的相互作用为肿瘤学提供了一个有吸引力的药物靶点。这种相互作用的小分子抑制剂不仅为阻断蛋白-蛋白相互作用提供了有力证据,而且作为生物探针也非常有用,并最终成为新的治疗方法。在这里,提供了对 p53-MDM2 相互作用的已授权小分子抑制剂的全面综述。这些抑制剂分为八类化合物,包括顺式咪唑啉类、苯并二氮杂䓬类、稠合吲哚类、取代哌嗪类、取代哌啶类、芳基硼酸类、螺吲哚类和α-螺旋模拟化合物。顺式咪唑啉类(例如,Nutlins)是 p53-MDM2 相互作用的选择性和有效抑制剂,有选择的例子在纳摩尔范围内表现出效力。Nutlins 诱导 p53 野生型细胞凋亡,并在小鼠异种移植模型中显示出体内疗效。在本综述中简要讨论的其他策略,以及目前正在探索靶向 p53 途径的策略,包括抑制 MDM2 介导的 p53 泛素化和使用小分子恢复突变型 p53 蛋白的 DNA 结合活性。

相似文献

1
Patented small molecule inhibitors of p53-MDM2 interaction.专利的 p53-MDM2 相互作用小分子抑制剂。
Expert Opin Ther Pat. 2006 Feb;16(2):165-88. doi: 10.1517/13543776.16.2.165.
2
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.用于癌症治疗的p53-HDM2相互作用小分子抑制剂。
Expert Opin Investig Drugs. 2008 Dec;17(12):1865-82. doi: 10.1517/13543780802493366.
3
Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.分子建模方法在抗癌治疗新药发现中的应用:p53-MDM2 相互作用及其小分子抑制作用的研究。
Curr Med Chem. 2010;17(28):3142-54. doi: 10.2174/092986710792232021.
4
Small molecule protein-protein inhibitors for the p53-MDM2 interaction.用于p53-MDM2相互作用的小分子蛋白质-蛋白质抑制剂。
Curr Top Med Chem. 2007;7(10):952-60. doi: 10.2174/156802607780906762.
5
Ordering of the N-terminus of human MDM2 by small molecule inhibitors.小分子抑制剂对人 MDM2 N 端的排序。
J Am Chem Soc. 2012 Oct 17;134(41):17059-67. doi: 10.1021/ja305839b. Epub 2012 Oct 5.
6
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).MDM2拮抗剂作为急性髓系白血病的一种新型治疗选择:关于idasanutlin(RG7388)治疗潜力的观点
Onco Targets Ther. 2019 Apr 16;12:2903-2910. doi: 10.2147/OTT.S172315. eCollection 2019.
7
Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core.基于咪唑啉核心的新型p53-MDM2相互作用抑制剂的合成设计与生物学评价
Pharmaceuticals (Basel). 2022 Apr 2;15(4):444. doi: 10.3390/ph15040444.
8
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives.用于癌症治疗的小分子MDM2/X抑制剂和PROTAC降解剂:进展与展望
Acta Pharm Sin B. 2020 Jul;10(7):1253-1278. doi: 10.1016/j.apsb.2020.01.003. Epub 2020 Jan 14.
9
Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition.非对称顺式二苯乙烯二胺的有机催化、非对映和对映选择性合成:用于制备用于蛋白质-蛋白质抑制的单一对映体顺式咪唑啉的平台。
J Org Chem. 2014 Aug 1;79(15):6913-38. doi: 10.1021/jo501003r. Epub 2014 Jul 14.
10
Environment-sensitive turn-on fluorescent probes for p53-MDM2 protein-protein interaction.用于p53-MDM2蛋白质-蛋白质相互作用的环境敏感型开启荧光探针。
Medchemcomm. 2017 Jul 3;8(8):1668-1672. doi: 10.1039/c7md00287d. eCollection 2017 Aug 1.

引用本文的文献

1
Chemical Variations on the p53 Reactivation Theme.p53 再激活主题上的化学变化
Pharmaceuticals (Basel). 2016 May 13;9(2):25. doi: 10.3390/ph9020025.
2
The p53-MDM2/MDMX axis - A chemotype perspective.p53-MDM2/MDMX轴——从化学型角度看
Medchemcomm. 2011;2:246-260. doi: 10.1039/C0MD00248H.
3
On the industrial applications of MCRs: molecular diversity in drug discovery and generic drug synthesis.关于磁流变弹性体的工业应用:药物发现和仿制药合成中的分子多样性。
Mol Divers. 2010 Aug;14(3):513-22. doi: 10.1007/s11030-010-9225-x. Epub 2010 Mar 16.
4
A novel strategy to assemble the beta-diketo acid pharmacophore of HIV integrase inhibitors on purine nucleobase scaffolds.一种在嘌呤核苷酸碱基支架上组装HIV整合酶抑制剂的β-二酮酸药效基团的新策略。
J Org Chem. 2007 Oct 26;72(22):8577-9. doi: 10.1021/jo701336r. Epub 2007 Oct 5.